{"version":"1.0","type":"link","title":"Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint.","author_name":"Castagnetti F 외","author_url":"https://prs-insight.online/author/Castagnetti%20F","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/163956","thumbnail_width":1200,"thumbnail_height":630}